ClinicalTrials.gg
Status unknownNCT05498558TSOPFPATEPTUpdated Aug 12, 2022

The Selection of Pregnancy for Patients After Tubal Ectopic Pregnancy Treatment

An observational study in Tubal-preserving Treatment of Tubal Ectopic Pregnancy, Tubal Pregnancy and Pregnancy Preparation, sponsored by Shanghai First Maternity and Infant Hospital. Status unknown at 1 site in China. Open to female participants aged 18 Years to 41 Years. Per ClinicalTrials.gov, last updated 2022-08-12.

Sponsored by Shanghai First Maternity and Infant Hospital · Observational

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 41 Years
Sex
Female
01

Study summary

The incidence of re-ectopic pregnancy in patients with tubal ectopic pregnancy increases significantly, which may be related to the condition of the fallopian tubes, such as tubal inflammation, tubal obstruction and other high-risk factors that may lead to tubal ectopic pregnancy; it is also associated with the treatment of the previous tubal ectopic pregnancy. Compared with salpingectomy, the treatment of preserving the fallopian tubes increased the incidence of re-ectopic pregnancy while increasing the pregnancy rate of the patient. For tubal-preserving patients, the most common option currently used is to recommend that monitoring ovulation during each menstrual cycle if they choose to conceive naturally rather than IVF. If ovulation occures on the healthy side of the ovary, it may be considered to try to conceive; Otherwise, contraception is recommended. However, there are uncertainties about this option. Based on this, we intend to conduct a multicenter clinical trial to verify the effectiveness of the ovulation preparation regimen on the healthy side of ovary.

Read the detailed description

Tubal ectopic pregnancy is a disease that seriously affects women's physical and mental health and reproductive health, not only can there be some short-term complications such as rupture of tubal pregnancy and massive bleeding in the abdominal cavity, but also can lead to a decrease in female fertility, and the incidence of subsequent ectopic pregnancy has increased significantly. In recent years, with the development of diagnosis and treatment methods, the proportion of serious clinical events such as rupture of tubal pregnancy and massive hemorrhage in patients has decreased significantly. However, there is little research on the long-term damage of tubal pregnancy to women's fertility, especially how to avoid the occurrence of re-ectopic pregnancy, and there is no definitive and effective program.The incidence of re-ectopic pregnancy in patients with tubal ectopic pregnancy increases significantly, which may be related to the condition of the fallopian tubes, such as tubal inflammation, tubal obstruction and other high-risk factors that may lead to tubal ectopic pregnancy; it is also associated with the treatment of the previous tubal ectopic pregnancy. Compared with salpingectomy, the treatment of preserving the fallopian tubes increased the incidence of re-ectopic pregnancy while increasing the pregnancy rate of the patient.It is reported that the incidence of re-ectopic pregnancy in patients who choose salpingotomy is significantly higher than salpingectomy.Patients receiving conservative treatment and expectant treatment with methotrexate have a similar incidence of re-ectopic pregnancy as in patients receving salpingotomy.For tubal-preserving patients, the most common option currently used is to recommend that monitoring ovulation during each menstrual cycle if they choose to conceive naturally rather than IVF. If ovulation occures on the healthy side of the ovary, it may be considered to try to conceive; Otherwise, contraception is recommended. However, there are uncertainties about this option. Based on this, we intend to conduct a multicenter clinical trial to verify the effectiveness of the ovulation preparation program on the healthy side of ovary.We plan to randomly divide patients who meet the inclusion criteria into two groups:preparation for pregnancy in each ovulatory cycle and in healthy ovulatory cycle. Monitor the development of the patient's follicles each cycle, follow the patient to pregnancy, and analyze the patient's ovulation rate of healthy ovary, pregnancy rate, ectopic pregnancy rate and the time required from preparation to be pregnant, so as to determine whether the healthy side ovulation preparation program can improve the patient's normal pregnancy rate and reduce the ectopic pregnancy rate.

02

Conditions studied

  • Tubal-preserving Treatment of Tubal Ectopic Pregnancy
  • Tubal Pregnancy
  • Pregnancy Preparation
03

In context

Lead sponsor

Shanghai First Maternity and Infant Hospital is the lead sponsor of 48 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 41 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with fertility needs who received tubal-preserving treatment during prior tubal ectopic pregnant in Shanghai First Maternity and Infant Hospital, Shanghai Zhoupu Hospital, Shanghai Seventh People's Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. After tubal pregnancy treatment (including expectant therapy, medication, salpingotomy), the blood hCG value returns to normal;
  2. The patient has fertility requirements;
  3. The age of the patient is between 18-41 years old;
  4. Regular menstruation;
  5. There is no abnormality in the husband's semen examination;
  6. No history of sex hormone drugs in the 3 months prior to the examination;
  7. No underlying diseases such as heart, liver, kidneys and brain;
  8. No history of tuberculosis;
  9. Normal blood routine examination (WBC≥ 4*109/L, HB≥100g/L, ≥100*109/L);
  10. Normal liver and kidney function tests;
  11. Normal thyroid function;
  12. The patient can withstand and receive follicle monitoring during pregnancy;
  13. Negative for pregnancy test before treatment.

Exclusion criteria

Exclusion Criteria:

  1. Cervical pregnancy, cesarean scar pregnancy, cornual pregnancy, interstitial pregnancy;
  2. The age of the patient \< 18 years or > 41 years;
  3. Irregular menstruation or abnormal results of sex hormone tests during follow-up;
  4. Abnormal results of the man's semen examination during the follow-up period;
  5. The patient has a tendency to bleed easily;
  6. History of myometriosis and endometriosis;
  7. Abnormal blood routine examination or liver and kidney function;
  8. History of cardiovascular diseases, including severe hypertension, severe arrhythmias, history of myocardial infarction;
  9. History of or C infection and patient has a detectable viral load;
  10. Patients with active tuberculosis;
  11. History of malignant tumors;
  12. Unable to regularly monitor the follicles during pregnancy;
  13. Unconditional long-term follow-up;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ovulation occurs on the healthy side

    In tubal-presering patient who received treatment of tubal ectopic pregnancy,only when ovulation occurs on the healthy side of ovary,it may be considered to try to conceive; otherwise, contraception is recommended.

    Other: No intervention.

  • Ovulation occurs on the either side

    In tubal-presering patient who received treatment of tubal ectopic pregnancy,ovulation occurs on the either side of ovary,it may be considered to try to conceive.

    Other: No intervention.

Interventions

  • OtherNo intervention.

    No intervention.

06

What researchers measure

Primary outcomes

  1. Rate of tubal pregnancy within12 months in both groups of patients.

    Tubal ectopic pregnancy refers to the implantation of embryo in the fallopian tubes.

    Time frame: 2023.10

Secondary outcomes

  1. Rates of pregnancy and miscarriage within 12 months in both groups of patients.

    Clinical pregnancy is defined as ultrasound suggesting a gestational sac, with or without fetal heartbeat; miscarriage is defined as ultrasound suggesting that the fetus is inanimate or that the fetus has miscarried spontaneously.

    Time frame: 2023.10

07

Study locations

1 site
  • Shanghai First Maternity and Infant Hospital
    Shanghai, Shanghai 200120, China
08

References and documents

Publications

  • Mol F, van Mello NM, Strandell A, Strandell K, Jurkovic D, Ross J, Barnhart KT, Yalcinkaya TM, Verhoeve HR, Graziosi GCM, Koks CAM, Klinte I, Hogstrom L, Janssen ICAH, Kragt H, Hoek A, Trimbos-Kemper TCM, Broekmans FJM, Willemsen WNP, Ankum WM, Mol BW, van Wely M, van der Veen F, Hajenius PJ; European Surgery in Ectopic Pregnancy (ESEP) study group. Salpingotomy versus salpingectomy in women with tubal pregnancy (ESEP study): an open-label, multicentre, randomised controlled trial. Lancet. 2014 Apr 26;383(9927):1483-1489. doi: 10.1016/S0140-6736(14)60123-9. Epub 2014 Feb 3. PubMed 24499812 ↗

Individual participant data

Plan to share: Undecided — IPD sharing plan is undecided now.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2023; primary completion for Oct 2023, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Aug 12, 2022
StartEst.
Jan 1, 2023
Primary completionEst.
Oct 30, 2023
CompletionEst.
Dec 31, 2023
Last update
Aug 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05498558
Lead sponsor
Shanghai First Maternity and Infant Hospital
Collaborators
Shanghai 7th People's Hospital, Shanghai Zhoupu Hospital, Shanghai Pudong Hospital
Responsible party
Sponsor
First posted
Aug 12, 2022
Start date
Jan 1, 2023 (estimated)
Primary completion
Oct 30, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Aug 12, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion